update
US FDA issues Dr Reddy's with Form 483 for UK plant
The US Food and Drug Administration (FDA) has found problems at a Dr Reddy’s API plant in the UK.
The Indian drug firm announced the inspection in a Bombay Stock Exchange (BSE) filing on Friday, explaining that agency inspectors who visited its facility in Mirfield, Yorkshire issued it with a Form 483 detailing three observations.
Dr Reddy's declined to provide details of the obervations, but did confirm that the plant will continue to supply the US, UK and European markets.
